As a shareholder for many years I have seen and dealt with the ongoing, but slow, progression of Brilacidin, the failure of Prurisol and the disappointment of no partner (as of yet) for B-OM. However, the very current excitement of B for C is all that matters. Proving itself to two government laboratories for right to proceed to trials is on the line and incredible news. It leads to money and game changing developments for Ipix. Everything else can for the time being be put aside. Successful testing leads to a successful Ipix which leads to a major re-evaluation of share price. QED.
Market Data 
Markets 
AI
